Problem: Select the hypothesis that is best written to test biological phenomena. Group of answer choices Aducanumab will reduce amyloid-beta aggregation, because it received FDA approval. Aducanumab, co-administered with occupational therapy, will help patients diagnosed with Alzheimer's Disease. Abucanumab usage will reduce the likelihood of depression in patients diagnosed with Alzheimer's Disease. Aducanumab will help patients diagnosed with Alzheimer's Disease.